Commercialization Roadmap Validated with Three-digit Million-dollar Revenue: Insilico Medicine Announces Interim Results for the First Half of 2026
<p>CAMBRIDGE, Mass., Aug. 26, 2026 /PRNewswire/ -- Insilico Medicine (HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, recently released its interim results report for 2026. The report shows that the Company achieved total revenue of US$106....</p>
Read original article ↗
Related Articles
Taming Hybrid Cloud Chaos: Secure and Efficient Kubernetes Across Clouds
Extending containerized applications to hybrid cloud and edge infrastructure often doubles operational overhead before d